Burns J W & Co. Inc. NY Acquires Shares of 1,040 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Burns J W & Co. Inc. NY bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,040 shares of the biopharmaceutical company’s stock, valued at approximately $1,001,000.

A number of other institutional investors also recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 22.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 2,365 shares of the biopharmaceutical company’s stock valued at $2,276,000 after acquiring an additional 426 shares during the last quarter. Trifecta Capital Advisors LLC raised its position in Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Trifecta Capital Advisors LLC now owns 3,298 shares of the biopharmaceutical company’s stock worth $3,174,000 after purchasing an additional 765 shares during the last quarter. Asio Capital LLC raised its position in Regeneron Pharmaceuticals by 1.7% in the 1st quarter. Asio Capital LLC now owns 2,545 shares of the biopharmaceutical company’s stock worth $2,450,000 after purchasing an additional 43 shares during the last quarter. Atlantic Union Bankshares Corp raised its position in Regeneron Pharmaceuticals by 8.0% in the 1st quarter. Atlantic Union Bankshares Corp now owns 1,549 shares of the biopharmaceutical company’s stock worth $1,491,000 after purchasing an additional 115 shares during the last quarter. Finally, Courier Capital LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $957,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Truist Financial restated a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. UBS Group upped their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Bank of America upped their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Finally, JPMorgan Chase & Co. upped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,027.55.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $0.17 during trading on Friday, reaching $1,051.03. 750,619 shares of the company’s stock traded hands, compared to its average volume of 469,667. The company has a market capitalization of $115.81 billion, a P/E ratio of 31.05, a PEG ratio of 2.17 and a beta of 0.13. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The firm’s 50-day moving average is $984.27 and its 200 day moving average is $950.40. Regeneron Pharmaceuticals, Inc. has a 1 year low of $688.52 and a 1 year high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The disclosure for this sale can be found here. Insiders have sold 61,971 shares of company stock valued at $61,217,654 in the last quarter. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.